Christos Hatzis
@chatzis28.bsky.social
Translational scientist advancing drug development for cancer and other diseases. Bridging research and patient care
“If the claim stands, it would be a scientific milestone for the field of topological quantum computing and physics beyond,” says Scott Aaronson. However, 'Topological quantum computing is “probably 20–30 years behind the other platforms” according to Ivar Martin of the Argonne National Lab
Microsoft has claimed to have made a topological qubit for quantum computing, although their paper published last week doesn't show (or claim) definitive evidence for it. What should we make of it all? I looked into it for @physicsworld.bsky.social
physicsworld.com/a/experts-we...
physicsworld.com/a/experts-we...
Experts weigh in on Microsoft's topological qubit claim – Physics World
Majorana zero modes exist in a curious superposition between peer review and press release
physicsworld.com
February 28, 2025 at 6:18 PM
“If the claim stands, it would be a scientific milestone for the field of topological quantum computing and physics beyond,” says Scott Aaronson. However, 'Topological quantum computing is “probably 20–30 years behind the other platforms” according to Ivar Martin of the Argonne National Lab
Reposted by Christos Hatzis
Does P=NP? It’s one of the most fundamental problems in computer science. But, what is P? What is NP? We explain in our complexity class primer: https://buff.ly/2zQbD7I
February 10, 2025 at 9:04 PM
Does P=NP? It’s one of the most fundamental problems in computer science. But, what is P? What is NP? We explain in our complexity class primer: https://buff.ly/2zQbD7I
Janux's T-cell engager against PSMA in metastatic prostate cancer shows very promising results, potentially challenging Pluvicto in mCRPC
investors.januxrx.com/investor-med...
investors.januxrx.com/investor-med...
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patients In 16 patients JANX007 displayed:...
investors.januxrx.com
December 3, 2024 at 1:27 PM
Janux's T-cell engager against PSMA in metastatic prostate cancer shows very promising results, potentially challenging Pluvicto in mCRPC
investors.januxrx.com/investor-med...
investors.januxrx.com/investor-med...
Reposted by Christos Hatzis
Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
November 29, 2024 at 4:00 PM
Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social